The global bovine respiratory disease treatment market size has been estimated at USD 44.9 million in 2020 and is forecasted to worth USD 124.6 million by 2025. This market is estimated to register a CAHR of 22.4% between 2020 to 2025.
Bovine respiratory diseases are the most common and expensive diseases that occur in cattle. Viruses, bacteria, and parasites viruses are the major factors for respiratory disease occurrence. Bovine herpesvirus (IBR), bovine parainfluenza virus (PI-3), Bovine coronavirus (BCV), and Bovine respiratory syncytial virus (BRSV) factors that affect the immune system of the calf, leads to weakness to cause diseases like pneumonia. Animals suffering from BRB often show signs of depression, cough, weight loss, fever, purulent nasal discharge, and abnormal pulmonary sound on auscultation. Various complexities are involved with the diagnosis of BRB.
MARKET DRIVERS:
Increasing beef consumption worldwide and growing disposable income in developing countries are majorly driving the global bovine respiratory disease treatment market growth.
The rising population is also influencing market growth. Increasing various infections such as bacteria, viruses, and parasites worldwide affect the calf immune system, leading to market growth. Rising demand for better quality bovine meat and products encourages cattle production expansion. Rapidly changing environmental factors, high prevalence of several causative agents for respiratory diseases among bovines are expected to drive the market growth.
Additionally, growing awareness among the consumers regarding healthy meat and animal health management practices, environmental protection guidelines are most likely to propel the bovine respiratory disease treatment market's market growth during the forecast period. Also, the increasing focus of key players on research and development of functional therapies is anticipated to influence the development of the market during the forecast period.
MARKET RESTRAINTS:
The global bovine respiratory disease treatment market is restricted by some challenging factors, such as complexities related to bovine respiratory disease diagnosis. The increasing cost of animal healthcare is slowly hindering the growth rate of the market. Moreover, lack of animal healthcare awareness in developing countries such as India and China, limited resources for animal treatments, and skilled veterinary professionals for animal treatments are considered the restricting factors for market growth.
Impact of COVID-19 on Bovine respiratory disease treatment market:
COVID-19 is an infectious disease which is caused by the most recent novel coronavirus. The World Health organization announced COVID-19 as the emergence of healthcare. Due to the sudden outbreak, a nationwide lockdown had been imposed. The outbreak of COVID-19 has shown a positive and negative impact on the pharmaceutical and life sciences market.
COVID-19 was first arrived as a regional pandemic and became a global outbreak. During the first half of 2020, the bovine respiratory disease treatment market had experienced a growth decline due to the covid-19 outbreak. Amid the ongoing COVID-19 pandemic, the world has witnessed a massive surge of cases in the first period of 2020. Several confirmed cases and deaths had been reported during the period. Apart from the nationwide lockdown, the hospital had an increased testing rate to combat COVID-19. Most of the bovine respiratory disease treatments had been postponed.
The latter period of 2020 has witnessed significant market growth. After the lockdown, the demand for animal treatment has been increased. Animal treatments have resumed. The market is expected to have better growth during the forecast period.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Treatment Type and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co., Merial S.A.S, Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S.A, Ceva Sante Animale and Vétoquinol S.A. |
This research report on the global bovine respiratory disease treatment market has been segmented and sub-segmented based on treatment type and region.
Bovine Respiratory Disease Treatment Market - By Treatment Type:
Based on treatment type, Antibiotics and anti-inflammatory drugs are now being used for combination treatment and are expected to improve the success rate of the treatment.
The anti-parasiticides segment is predicted to record a healthy CAGR during the forecast period. Anti-parasiticides are one of the antimicrobial drugs that target bacteria and antifungals. The anti-parasiticides segment growth is driven by the Increasing various infections such as bacteria, virus, and parasites viruses and Animals suffering from BRB.
Bovine Respiratory Disease Treatment Market - By Region:
Geographically, North America leads the market due to the more significant occurrence of bovine respiratory disease. In the Asia Pacific region, China and India have greater cattle adoption and are expected to grow fast.
North America held the largest share in the global bovine respiratory disease market in 2019 and forecasted to continue the domination throughout the forecast period. Factors such as increasing domestic production, consumption, and bovine meat exports are majorly driving this regional market. According to recent reports, America held the majority contributor to bovine respiratory disease treatment market growth. America has produced approximately 30 million tonnes of beef in the forecast period. BRD is the most endemic disease in North America.
The European market held a substantial market share globally in 2019 and is projected to register a robust CAGE during the forecast period due to the increasing growth factors such as rising population and growing meat intake in this region.
The Asia Pacific market is forecasted to be the most lucrative region globally between 2020 to 2025. It is a known fact that the consumption of bovine meat is high in countries such as China. Growing disposable income in developing countries such as India and China are considered the major driving factor for the bovine respiratory disease market in this region.
The Latin American market was growing steadily in the recent past and will register healthy growth during the forecast period. Rising focus on veterinary health, small companies are coming up with novel therapeutics in this region and increasing demand for better quality meat and products to encourage cattle production.
In MEA, the market is expected to grow at a promising growth rate during the forecast period. Factors such as increasing disposable income, rising consumption of animal meat in the counties such as Kuwait, United Arab Emirates, and growing awareness among the consumers regarding healthy meat and animal health management practices environmental protection guidelines are most likely to propel the market growth bovine respiratory disease treatment market.
PROMISING PLAYERS IN THIS MARKET:
Some of the noteworthy companies leading the global bovine respiratory disease treatment market profiled in the report are Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co., Merial S.A.S., Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S.A. and Ceva Sante Animale and Vétoquinol S.A.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type of Treatment
5.1.1 Anti-Infectious Agents
5.1.1.1 Antibiotics
5.1.1.2 Sulfas
5.1.2 Anti-Parasiticides
5.1.3 Bronchodilators
5.1.4 Oral Rehydration Fluids
5.1.5 Non-Steroidal Anti-Inflammatories
5.1.6 Mucolytics
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Argentina
6.4.5 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Zoetis Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck & Co. Inc.
8.3 Bayer Corporation
8.4 Eli Lilly & Co.
8.5 Merial S.A.S
8.6 Boehringer Ingelheim Vetmedica
8.7 Novartis Animal Health
8.8 Vibrac S.A
8.9 Ceva Sante Animale
8.10 Vétoquinol S.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
